mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.
Liang SQ, Bührer ED, Berezowska S, Marti TM, Xu D, Froment L, Yang H, Hall SRR, Vassella E, Yang Z, Kocher GJ, Amrein MA, Riether C, Ochsenbein AF, Schmid RA, Peng RW.
Liang SQ, et al. Among authors: marti tm.
Oncogene. 2019 Jan;38(5):622-636. doi: 10.1038/s41388-018-0479-6. Epub 2018 Aug 31.
Oncogene. 2019.
PMID: 30171261